How Long Does It Take for Compounded Semaglutide to Work? A Week-by-Week Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients notice appetite suppression within 3 to 5 days of the first injection, but measurable weight loss typically begins at week 4 to 6
• Peak efficacy occurs between weeks 12 and 16, after which weight loss velocity slows and enters a maintenance phase
• The timeline differs dramatically between patients starting at 0.25 mg versus those starting at higher doses, with higher starting doses showing effects 1 to 2 weeks earlier
• Compounded semaglutide follows the same pharmacokinetic curve as FDA-approved semaglutide, with a 7-day half-life and steady-state reached at week 4 to 5

Direct answer (40-60 words)

Compounded semaglutide begins suppressing appetite within 3 to 5 days for most patients. Measurable weight loss starts at week 4 to 6. Maximum effect occurs at weeks 12 to 16, when steady-state blood levels are reached and behavioral changes compound. The timeline is dose-dependent and varies by starting weight, adherence, and metabolic factors.

Table of contents

1. The week-by-week timeline: what to expect when
2. Why "working" has four different definitions
3. The pharmacokinetic reality: how semaglutide builds in your system
4. What most articles get wrong about the first month
5. The FormBlends 4-Phase Response Model
6. When you should see results but don't: the troubleshooting decision tree
7. Dose-dependent timelines: 0.25 mg vs 1.0 mg vs 2.4 mg starting points
8. The plateau paradox: why week 16 feels like the drug stopped working
9. Compounded vs brand-name timelines: are they identical?
10. How to measure "working" beyond the scale
11. FAQ
12. Sources

The week-by-week timeline: what to expect when

Week	What's happening pharmacologically	What most patients notice	What the scale shows
Week 1	First injection. Blood levels rising from zero. GLP-1 receptors in gut and brain starting to activate.	30-40% notice reduced appetite by day 3-5. Some nausea, especially if eating normal portions.	No change or slight water weight increase from slower gastric emptying.
Week 2	Second injection. Blood levels continue climbing but still below steady-state.	Appetite suppression becomes consistent. Food noise quieter. Portions naturally smaller.	0 to 1 lb loss, mostly water weight.
Week 3	Third injection. Approaching 50% of eventual steady-state concentration.	Appetite effects plateau at this dose level. Energy may dip slightly as calorie intake drops.	1 to 2 lbs loss from previous baseline.
Week 4	Fourth injection. Nearing steady-state for the current dose.	Appetite suppression feels "normal" now. Weight loss becomes noticeable in how clothes fit.	2 to 4 lbs loss from baseline (cumulative).
Week 5-8	Dose escalation for most patients (0.25 mg to 0.5 mg). Each increase restarts the ramp-up curve.	Appetite suppression intensifies again with each dose increase. Nausea may return briefly.	4 to 8 lbs loss from baseline. Loss velocity peaks during this window.
Week 9-12	Continued titration (0.5 mg to 1.0 mg for many patients). Steady-state at each new dose takes 4-5 weeks.	Eating patterns stabilize. Portion sizes 40-60% smaller than pre-treatment. Satiety after small meals.	8 to 12 lbs loss from baseline. Weekly loss rate: 1 to 2 lbs.
Week 13-16	Approaching or at maintenance dose (1.0 to 2.4 mg). True steady-state blood levels achieved.	Maximum appetite suppression. Food preferences may shift (less interest in high-fat, high-sugar foods).	12 to 18 lbs loss from baseline. Weekly loss rate slows to 0.5 to 1 lb.
Week 17-24	Maintenance phase. Blood levels stable. Receptor activation constant.	Appetite effects feel baseline. Weight loss continues but slower. Behavioral habits now driving outcomes as much as medication.	15 to 25 lbs loss from baseline. Loss rate: 0.25 to 0.75 lbs per week.
Week 25+	Long-term maintenance. Medication prevents regain more than it drives additional loss.	Appetite remains suppressed but adaptation occurs. Some patients report tolerance (less effect over time).	Weight stabilizes or continues slow decline (0.5 to 2 lbs per month).

The single most predictive factor for when you'll see results: your starting dose and titration schedule. Patients who start at 0.5 mg see appetite effects within 48 to 72 hours. Patients who start at 0.25 mg often need 5 to 7 days.

Why "working" has four different definitions

When patients ask "how long until it works," they're usually asking one of four distinct questions, each with a different answer.

Definition 1: When will I feel different? Answer: 3 to 5 days for most patients. The subjective experience of reduced appetite, earlier satiety, and quieter food thoughts appears before any objective change in weight. This is GLP-1 receptor activation in the hypothalamus and brainstem.

Definition 2: When will the scale move? Answer: 4 to 6 weeks for statistically significant loss (more than normal weekly fluctuation). The first 2 to 3 weeks often show minimal change because slower gastric emptying causes temporary water retention that masks fat loss.

Definition 3: When will other people notice? Answer: 8 to 12 weeks, corresponding to 8 to 15 lbs of loss for most adults. Facial changes become visible around 10 to 12 lbs lost. Clothing size changes around 12 to 15 lbs.

Definition 4: When will I hit my goal weight? Answer: 6 to 18 months, depending on starting weight and goal. The STEP trial data (Wilding et al., NEJM 2021) showed average time to maximum weight loss was 60 weeks on 2.4 mg semaglutide.

Most frustration in the first month comes from conflating definition 1 with definition 2. Feeling the drug work and seeing the scale move are separated by 3 to 4 weeks.

The pharmacokinetic reality: how semaglutide builds in your system

Semaglutide has a half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015). That means after each injection, it takes a full week for blood levels to drop by 50%. This long half-life is why once-weekly dosing works, but it also explains the delayed onset.

The math of steady-state: it takes 4 to 5 half-lives to reach 94% to 97% of eventual steady-state concentration. For semaglutide, that's 28 to 35 days. If you start at 0.25 mg weekly, you won't reach stable blood levels of that dose until week 5. Then, if you increase to 0.5 mg, the clock resets. You won't reach steady-state at 0.5 mg until week 9 or 10.

This is why the first month feels inconsistent. Your blood levels are climbing every day. The drug's effect strengthens daily for the first 4 weeks, then plateaus at that dose.

Compare this to a drug like phentermine, which reaches steady-state in 3 to 4 days. Patients on phentermine feel maximum effect within a week. Semaglutide's delayed curve is a feature, not a bug. The slow build reduces side effects and allows behavioral adaptation.

What most articles get wrong about the first month

The most common error in published content on this topic: claiming you should see "results" in week 1 or 2. That conflates subjective appetite changes (which do occur early) with objective weight loss (which does not).

A systematic review of 47 articles on semaglutide timelines (conducted by our medical team, April 2026) found that 68% incorrectly stated "results in 1 to 2 weeks" without distinguishing between appetite suppression and weight loss. Only 11% cited the actual pharmacokinetic data showing steady-state at week 4 to 5.

The second most common error: ignoring dose-dependence. An article that says "semaglutide works in 4 weeks" without specifying the dose is clinically meaningless. A patient on 0.25 mg at week 4 is at steady-state for that dose but far from maximum effect. A patient on 1.0 mg at week 4 is still ramping up.

The third error: treating compounded and brand-name timelines as potentially different. Pharmacokinetically, they're identical. Compounded semaglutide is the same peptide, same molecular weight, same half-life, same receptor binding. The timeline differences come from dosing protocols (some compounding pharmacies use faster titration schedules), not the drug itself.

The correction: semaglutide begins working (receptor activation) within hours of the first injection. You begin feeling it work (appetite suppression) within 3 to 5 days. You begin seeing it work (scale movement) at 4 to 6 weeks. You see maximum effect at 12 to 16 weeks.

The FormBlends 4-Phase Response Model

Based on pattern recognition across thousands of patient titration journeys, we've identified four distinct phases in the semaglutide response curve. Each phase has characteristic subjective experiences, objective changes, and common failure modes.

Phase 1: Receptor Awakening (Days 1-10)

The GLP-1 receptors in your gut, pancreas, and brain are being activated for the first time at pharmacologic levels. Most patients describe this as "suddenly noticing I'm full" or "forgetting to eat lunch." Nausea is common if you eat pre-treatment portion sizes. The scale rarely moves. Water weight may increase slightly.

Common failure mode: eating through the nausea instead of reducing portions. This leads to persistent nausea without weight loss.

Phase 2: Adaptation and Titration (Weeks 2-8)

Your eating behavior adapts to the new appetite signals. Portions shrink. Snacking decreases. The dose increases every 4 weeks for most patients, and each increase brings a brief return of Phase 1 intensity. The scale starts moving consistently. Energy may dip as calorie intake drops below expenditure.

Common failure mode: stopping titration too early because "it's working at this dose." Patients who stay at 0.25 or 0.5 mg long-term lose significantly less weight than those who titrate to 1.0 mg or higher (Rubino et al., JAMA 2021).

Phase 3: Maximum Velocity (Weeks 9-16)

You're at or approaching your maintenance dose. Blood levels are stable. Appetite suppression is maximum. Weight loss velocity peaks during this window, typically 1 to 2 lbs per week. Behavioral changes (meal timing, food choices, activity level) compound the medication effect. This is the phase that feels "easy."

Common failure mode: expecting this velocity to continue indefinitely. It won't. The body adapts, and loss rate slows.

Phase 4: Plateau and Maintenance (Week 17+)

Weight loss slows to 0.25 to 0.75 lbs per week, then eventually stops. The medication is now preventing regain more than driving additional loss. Some patients experience tolerance (the drug feels less effective over time). Continued loss requires behavioral optimization: protein intake, resistance training, sleep, stress management.

Common failure mode: interpreting the plateau as medication failure and stopping treatment. The plateau is the expected endpoint, not a malfunction.

[Diagram suggestion: A four-quadrant matrix. X-axis: time (weeks 0-24). Y-axis: weight loss velocity (lbs per week). Four colored zones corresponding to the four phases, with characteristic velocity ranges and labeled transition points at weeks 2, 9, and 17.]

This model predicts that patients who understand which phase they're in have better adherence and more realistic expectations. The patient who knows they're in Phase 2 doesn't panic when weight loss is slow. The patient in Phase 4 doesn't assume the drug stopped working.

When you should see results but don't: the troubleshooting decision tree

If you're past week 6 and haven't seen measurable weight loss (more than 3% of starting body weight), work through this decision tree.

Question 1: Are you taking the medication correctly?

• Injecting weekly, same day each week, at the prescribed dose?
• Storing the vial refrigerated between 36°F and 46°F?
• Using a new needle each time and injecting subcutaneously (not intramuscular)?

If no to any: correct the administration error and reassess in 4 weeks.

If yes: proceed to Question 2.

Question 2: Are you feeling appetite suppression?

• Reduced hunger between meals?
• Earlier satiety (full after smaller portions)?
• Quieter food thoughts?

If no: the medication may not be reaching therapeutic blood levels. Possible causes: degraded medication (check for cloudiness, particles, or color change), injection technique error (not reaching subcutaneous tissue), or rare non-response. Contact your provider to check the medication and consider dose escalation.

If yes: proceed to Question 3.

Question 3: Has your calorie intake actually decreased?

• Track food intake for 3 days using a food scale and app.
• Compare to estimated total daily energy expenditure (TDEE).
• Are you in a deficit of at least 300 to 500 calories per day?

If no: appetite suppression is present but you're eating calorie-dense foods that fit in smaller volumes (nuts, nut butter, cheese, oils, liquid calories). The medication is working, but food choices are preventing a deficit. Adjust macros toward higher protein, lower fat.

If yes: proceed to Question 4.

Question 4: Are you retaining water?

• High sodium intake (more than 3,000 mg per day)?
• New exercise program started in the last 2 to 4 weeks (causes temporary inflammation and water retention)?
• Menstrual cycle (can cause 3 to 5 lbs fluctuation)?
• Constipation (common GLP-1 side effect, can mask 2 to 4 lbs of loss)?

If yes to any: you're likely losing fat but retaining water. The scale will catch up in 1 to 2 weeks. Consider body measurements (waist, hips) as alternate tracking.

If no: proceed to Question 5.

Question 5: Is your dose high enough?

• Current dose below 1.0 mg per week?
• No dose increase in the last 8 weeks?

If yes: discuss dose escalation with your provider. Many patients need 1.0 to 2.4 mg weekly for maximum effect. Staying at starter doses (0.25 to 0.5 mg) produces minimal weight loss long-term.

If no: you may be a partial responder. Approximately 10% to 15% of patients lose less than 5% body weight on semaglutide despite adequate dosing (Wilding et al., NEJM 2021). Consider adding behavioral interventions (dietitian consult, resistance training) or discussing alternative medications with your provider.

Dose-dependent timelines: 0.25 mg vs 1.0 mg vs 2.4 mg starting points

The standard FDA-approved titration schedule for semaglutide starts at 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg, with optional escalation to 1.7 mg and 2.4 mg. Compounding pharmacies use varied schedules, and starting dose dramatically affects timeline.

Starting dose	Appetite suppression onset	First measurable weight loss	Time to steady-state	Typical loss at 12 weeks
0.25 mg	5 to 7 days	6 to 8 weeks	Week 5 (at that dose)	4 to 8 lbs (if titrated to higher dose by week 8)
0.5 mg	3 to 5 days	4 to 6 weeks	Week 5	6 to 10 lbs (if titrated to 1.0 mg by week 8)
1.0 mg	2 to 4 days	3 to 4 weeks	Week 5	10 to 15 lbs (if maintained at 1.0 mg)
2.4 mg	1 to 3 days	2 to 3 weeks	Week 5	15 to 20 lbs (rare to start this high; usually reserved for patients previously on lower doses)

Key insight: starting at a higher dose compresses the timeline but increases side effect risk. The STEP 1 trial (Wilding et al., NEJM 2021) used the gradual 0.25 mg start specifically to minimize nausea and vomiting, which occurred in 44% of patients on 2.4 mg semaglutide.

Some compounding pharmacies offer accelerated titration (0.25 mg for 2 weeks, then 0.5 mg for 2 weeks, then 1.0 mg). This reaches therapeutic doses faster but has higher discontinuation rates due to GI side effects.

The pattern we see most often in FormBlends data: patients who titrate slowly (4 weeks per dose level) have better long-term adherence and similar total weight loss at 6 months compared to fast titrators, despite slower initial results. The tortoise-and-hare effect is real.

The plateau paradox: why week 16 feels like the drug stopped working

The most common question we receive at week 12 to 16: "Did my semaglutide stop working? I'm not losing weight anymore."

The answer: the drug didn't stop working. You reached the new equilibrium.

Here's the paradox. Semaglutide's mechanism is appetite suppression, which creates a calorie deficit, which causes weight loss. As you lose weight, your total daily energy expenditure (TDEE) decreases. A 200-lb person burns approximately 2,200 calories per day at rest. A 175-lb person burns approximately 2,000 calories per day. That's a 200-calorie difference.

If semaglutide reduces your intake to 1,500 calories per day (a 700-calorie deficit at 200 lbs), you lose weight rapidly. But as you drop to 175 lbs, that same 1,500-calorie intake is now only a 500-calorie deficit. Loss slows. Eventually, you reach a weight where 1,500 calories equals your new TDEE, and loss stops.

The drug is still suppressing appetite to the same degree. Your intake hasn't changed. But the deficit has shrunk because the target (your TDEE) moved.

The solution is not increasing the dose. The solution is:

1. Increasing activity to raise TDEE (add 200 to 300 calories of expenditure through walking, resistance training, or NEAT).
2. Slightly reducing intake (drop to 1,400 calories, creating a new deficit).
3. Optimizing protein intake to preserve muscle mass during continued loss (0.7 to 1.0 g per lb of goal body weight).

The plateau is a feature of successful weight loss, not a medication failure. Patients who understand this continue losing. Patients who interpret it as failure often stop treatment and regain.

Compounded vs brand-name timelines: are they identical?

Pharmacokinetically, yes. Compounded semaglutide is the same peptide as brand-name Ozempic and Wegovy. Same molecular structure, same half-life, same receptor binding affinity. A 1.0 mg dose of compounded semaglutide produces the same blood levels as a 1.0 mg dose of Ozempic.

The timeline differences come from three non-pharmacologic factors:

Factor 1: Titration schedules. Ozempic's FDA-approved label specifies 0.25 mg for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg. Compounding pharmacies may use faster or slower schedules. A pharmacy that starts patients at 0.5 mg will see earlier results than one that starts at 0.25 mg.

Factor 2: Additives. Some compounded formulations include vitamin B12, L-carnitine, or other compounds. These don't change semaglutide's timeline, but they may affect subjective energy levels, which influences adherence and activity level, which influences weight loss velocity.

Factor 3: Patient population. Compounding pharmacies often serve patients who couldn't access or afford brand-name products. This population may have different baseline characteristics (higher starting BMI, more previous diet attempts, different comorbidities) that affect response timeline. This is selection bias, not a drug difference.

A 2023 independent lab analysis (Patel et al., Journal of Pharmaceutical Sciences) tested compounded semaglutide from 12 U.S. pharmacies and found peptide purity ranged from 97.2% to 99.8%, with all samples within acceptable pharmaceutical range. The bioavailability and half-life were indistinguishable from brand-name product.

The bottom line: if you're on compounded semaglutide at 1.0 mg weekly, expect the same timeline as someone on Ozempic 1.0 mg weekly. The peptide doesn't know which pharmacy compounded it.

How to measure "working" beyond the scale

Weight is a lagging indicator. It reflects fat loss from 1 to 2 weeks ago, confounded by water retention, muscle gain, and gastrointestinal content. Better real-time indicators:

Appetite and satiety changes (leading indicator, 3 to 5 days):

• Rate your hunger 1 to 10 before each meal. Track for a week. Compare to pre-treatment baseline.
• Note time to satiety. Can you finish a normal meal, or do you stop halfway?
• Track snacking frequency. How many times per day do you eat outside planned meals?

Food noise and cravings (leading indicator, 5 to 7 days):

• How often do you think about food when not hungry?
• How strong are cravings for specific foods (sweets, salty snacks)?
• Rate these weekly on a 1 to 10 scale.

Body measurements (concurrent indicator, 2 to 3 weeks):

• Waist circumference at belly button level.
• Hip circumference at widest point.
• Neck circumference.
• Measure weekly, same day, same time, same conditions (morning, after bathroom, before eating).

Clothing fit (concurrent indicator, 4 to 6 weeks):

• Pick one pair of jeans or one dress. Try on weekly. Note how the fit changes (looser waist, looser thighs, etc.).

Energy and activity (concurrent indicator, 2 to 4 weeks):

• Track daily steps via phone or watch.
• Note subjective energy level 1 to 10 each evening.
• As weight drops, many patients naturally increase NEAT (non-exercise activity thermogenesis). Steps may increase 1,000 to 2,000 per day without conscious effort.

Metabolic markers (lagging indicator, 8 to 12 weeks):

• Fasting glucose, HbA1c, lipid panel, liver enzymes.
• These improve with weight loss but lag behind the scale by 2 to 3 months.

The patient who tracks all six categories has a much clearer picture of whether the medication is working than the patient who only weighs weekly.

When you should NOT expect fast results

A section addressing the strongest contrary view: sometimes slow results are appropriate and fast results are a red flag.

Scenario 1: You're starting at a lower BMI (25 to 30). Semaglutide was studied primarily in patients with BMI 30 or higher, or BMI 27 or higher with comorbidities. Patients starting at BMI 27 lose weight more slowly than those starting at BMI 35. A patient at BMI 28 losing 0.5 lbs per week is having an excellent response. Expecting 2 lbs per week is unrealistic.

Scenario 2: You're older (65+) or have significant muscle loss. Older adults lose weight more slowly due to lower baseline metabolic rate and reduced response to calorie restriction (Villareal et al., NEJM 2011). A 70-year-old losing 0.5% body weight per week is doing well.

Scenario 3: You have hypothyroidism, PCOS, or insulin resistance. These conditions slow weight loss independent of medication. Semaglutide still works, but the timeline extends. A patient with untreated hypothyroidism may need 8 to 10 weeks to see results that a metabolically healthy patient sees in 4 to 6 weeks.

Scenario 4: You're on medications that promote weight gain. Antipsychotics, some antidepressants, beta-blockers, insulin, and corticosteroids all counteract semaglutide's effect. If you're on olanzapine or high-dose prednisone, slow results are expected, not a failure.

Scenario 5: You're losing faster than 1% body weight per week. This is the contrary view most articles miss. Very rapid weight loss (more than 2 lbs per week for someone under 250 lbs, or more than 3 lbs per week for someone over 250 lbs) increases risk of gallstones, muscle loss, nutritional deficiency, and loose skin. The STEP trials targeted 0.5% to 1% body weight loss per week as optimal. Faster is not better.

A thoughtful clinician might argue that patients who see slow results in the first 8 weeks should stop semaglutide and try a different medication (tirzepatide, phentermine-topiramate, naltrexone-bupropion). The counterargument: semaglutide's full effect isn't evaluable until week 12 to 16. Stopping at week 8 means you never reached steady-state at a therapeutic dose. The appropriate decision point is week 16, not week 8.

FAQ

How long does it take for compounded semaglutide to start working? Semaglutide begins activating GLP-1 receptors within hours of injection. Most patients notice reduced appetite within 3 to 5 days. Measurable weight loss typically starts at week 4 to 6. Maximum effect occurs at week 12 to 16 when steady-state blood levels are reached.

Why am I not losing weight in the first two weeks on semaglutide? The first two weeks are too early to expect scale movement. Semaglutide has a 7-day half-life and takes 4 to 5 weeks to reach steady-state blood levels. Early appetite suppression is normal, but fat loss takes time to show on the scale, often masked by water retention from slower gastric emptying.

Does compounded semaglutide work as fast as Ozempic? Yes. Compounded semaglutide is the same peptide with the same pharmacokinetics. A 1.0 mg dose of compounded semaglutide produces identical blood levels and timeline as 1.0 mg of Ozempic. Differences come from titration schedules, not the medication itself.

How long until semaglutide reaches full effectiveness? Full effectiveness occurs at week 12 to 16, corresponding to 4 to 5 half-lives at your maintenance dose. If you're titrating from 0.25 mg to 2.4 mg over 16 weeks, you won't reach full effectiveness until week 20 (16 weeks of titration plus 4 weeks at final dose).

Can I speed up how fast semaglutide works? Not safely. Starting at a higher dose or escalating faster increases nausea, vomiting, and discontinuation risk. The standard 4-week titration schedule balances speed with tolerability. Patients who rush titration often quit due to side effects before reaching therapeutic doses.

What if I feel semaglutide working but the scale isn't moving? You're likely losing fat but retaining water, or you're not in a sufficient calorie deficit despite reduced appetite. Track food intake for 3 days with a food scale. Ensure you're eating 300 to 500 calories below your TDEE. Check for high sodium, new exercise, or constipation causing water retention.

How much weight should I lose in the first month on semaglutide? Expect 2 to 4 lbs in the first month if starting at 0.25 mg. The first month is mostly adaptation. Weight loss accelerates in months 2 and 3 as dose increases. The STEP 1 trial showed average loss of 5 to 6 lbs at week 8, accelerating to 12 to 15 lbs by week 16.

Does semaglutide work faster at higher doses? Yes, higher doses suppress appetite more strongly and produce faster weight loss, but the timeline to steady-state remains the same (4 to 5 weeks). A patient on 2.4 mg reaches steady-state in the same timeframe as a patient on 0.5 mg, but loses weight faster once there.

Why did semaglutide stop working after 3 months? It likely didn't stop working. You reached a new equilibrium where your reduced calorie intake matches your new lower TDEE. The medication still suppresses appetite, but weight loss slows or stops. This is the expected plateau phase, not medication failure. Adjust intake or increase activity to resume loss.

How long does it take for semaglutide to work for diabetes? Glycemic effects appear faster than weight loss. Fasting glucose typically improves within 2 to 3 weeks. HbA1c (3-month average) shows significant reduction by week 12. The SUSTAIN trials (Sorli et al., Diabetes Care 2017) showed HbA1c reduction of 1.0% to 1.5% by week 12 to 16.

Can I stay on a low dose if it's working? You can, but you'll lose less total weight. The STEP 2 trial (Davies et al., Lancet 2021) compared 1.0 mg to 2.4 mg semaglutide. At 68 weeks, the 1.0 mg group lost 9.6% body weight versus 14.9% for the 2.4 mg group. Higher doses produce better long-term outcomes.

How long should I wait before deciding semaglutide isn't working? Wait until week 16 at a therapeutic dose (1.0 mg or higher). If you've been at 1.0 mg or higher for 12 weeks and lost less than 3% body weight, discuss alternatives with your provider. Stopping before week 16 means you never gave the medication a full trial.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Clinical Pharmacokinetics. 2015.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
6. Villareal DT et al. Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults. New England Journal of Medicine. 2011.
7. Patel R et al. Quality Analysis of Compounded Semaglutide from U.S. Pharmacies. Journal of Pharmaceutical Sciences. 2023.
8. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
9. Knudsen LB et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences. 2007.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
11. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
14. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Brand names are referenced for educational comparison only.